A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells - PubMed (original) (raw)
. 2002 May 15;62(10):2848-55.
Affiliations
- PMID: 12019163
A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells
Matthias Peipp et al. Cancer Res. 2002.
Abstract
A recombinant immunotoxin was constructed from the hybridoma antibody TH-69 directed against human CD7, a surface antigen of leukemic T cells. The antibody was subcloned as a single chain Fv (scFv) fragment and genetically linked to a truncated Pseudomonas exotoxin A fragment containing the catalytic domains II and III but lacking the receptor binding domain I. Domain I was replaced by the scFv, thus conferring restricted specificity for CD7-positive cells. The bacterially expressed and purified toxin retained binding specificity for CD7-positive cells. It promoted apoptosis in two CD7-positive cell lines derived from T-lineage acute lymphoblastic leukemias, CEM and Jurkat, but not in the CD7-negative B-lymphoid lines REH, Nalm-6, and SEM. Maximum killing in excess of 95% was reached after 96 h in CEM and Jurkat cells with a single dose of 100 ng/ml. Cells treated with a similarly constructed scFv-exotoxin A immunotoxin against melanoma-associated chondroitin sulfate proteoglycan, an antigen absent from leukemic T cells, remained unaffected. Lysis of target cells occurred via apoptosis as evidenced by staining with Annexin V and specific cleavage of poly(ADP-ribose) polymerase. Approximately 20% of leukemic cells from a patient with CD7-positive acute T-cell leukemia kept in long-term primary culture for 30 cell generations were killed within 96 h after treatment with the toxin. These findings justify further evaluation of the agent in view of potential therapeutic applications.
Similar articles
- Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W. Bremer E, et al. Cancer Res. 2005 Apr 15;65(8):3380-8. doi: 10.1158/0008-5472.CAN-04-2756. Cancer Res. 2005. PMID: 15833872 - Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK, Huhn M, Thepen T, Stöcker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, Finnern R, Barth S. Tur MK, et al. Cancer Res. 2003 Dec 1;63(23):8414-9. Cancer Res. 2003. PMID: 14679004 - A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, Birkmann J, Oduncu F, Emmerich B, Fey GH. Schwemmlein M, et al. Br J Haematol. 2006 Apr;133(2):141-51. doi: 10.1111/j.1365-2141.2005.05869.x. Br J Haematol. 2006. PMID: 16611304 - Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ, Pastan I. Kreitman RJ, et al. Leuk Lymphoma. 1994 Mar;13(1-2):1-10. Leuk Lymphoma. 1994. PMID: 8025511 Review. - Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy.
Dieffenbach M, Pastan I. Dieffenbach M, et al. Biomolecules. 2020 Jun 30;10(7):979. doi: 10.3390/biom10070979. Biomolecules. 2020. PMID: 32630017 Free PMC article. Review.
Cited by
- An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL).
Wang S, Zhang R, Zhong K, Guo W, Tong A. Wang S, et al. Biomolecules. 2024 Jan 15;14(1):106. doi: 10.3390/biom14010106. Biomolecules. 2024. PMID: 38254706 Free PMC article. - Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.
Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Png YT, et al. Blood Adv. 2017 Nov 21;1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928. eCollection 2017 Nov 28. Blood Adv. 2017. PMID: 29296885 Free PMC article. - Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies.
Krohn S, Holtrop T, Brandsma AM, Moerer P, Nederend M, Darzentas N, Brüggemann M, Klausz K, Leusen JHW, Peipp M. Krohn S, et al. Viruses. 2024 Apr 12;16(4):596. doi: 10.3390/v16040596. Viruses. 2024. PMID: 38675937 Free PMC article. - Potential prognostic biomarkers related to immunity in clear cell renal cell carcinoma using bioinformatic strategy.
Xiang Z, Shen E, Li M, Hu D, Zhang Z, Yu S. Xiang Z, et al. Bioengineered. 2021 Dec;12(1):1773-1790. doi: 10.1080/21655979.2021.1924546. Bioengineered. 2021. PMID: 34002666 Free PMC article. - A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Stockmeyer B, Berens C, Oduncu FS, Mackensen A, Fey GH. Schubert I, et al. MAbs. 2012 Jan-Feb;4(1):45-56. doi: 10.4161/mabs.4.1.18498. MAbs. 2012. PMID: 22327429 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials